BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 146.71% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 359.70K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 359.70K.
Overvalued
The company’s latest PE is -0.38, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.24M shares, decreasing 15.25% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.64.